Article
Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Drug metabolism and disposition: the biological fate of chemicals - 1 Nov 2010
Christopher Lisa J, Hong Haizheng, Vakkalagadda Blisse J, Clemens Pamela L, Su Hong, Roongta Vikram, Allentoff Alban, Sun Haojun, Heller Kevin, Harbison Christopher T, Iyer Ramaswamy A, Humphreys William G, Wong Tai, Zhang Steven
Abstract excerpt
(3R,4R)-4-Amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f][1,2,4]triazin-5-yl)methyl)-3-piperidinol (BMS-690514), an oral selective inhibitor of human epidermal growth factor receptors 1 (or epidermal growth factor receptor), 2, and 4, and vascular endothelial growth factor receptors 1, 2, and 3, is being developed as a treatment for patients with non-small-cell lung cancer and metastatic breast cancer. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.